

Press Release
July 19, 2021

Scandion Oncology announces that its President & CEO has bought 4,500 shares in Scandion Oncology

Scandion Oncology A/S (“Scandion Oncology”) announces that its President & CEO, Bo Rode Hansen, has bought additional 4,500 shares in Scandion Oncology resulting in a total holding on 40,400 shares in the Company.

For further information regarding Scandion Oncology A/S, please contact:

Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
E-mail: info@scandiononcology.com
Website: www.scandiononcology.com

The information was provided by the contact person above for publication on July 19, 2021.

About Scandion Oncology A/S

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. **Ticker: SCOL.**

For more information, please visit www.scandiononcology.com and sign up for news releases. For frequent updates, please also follow us on [LinkedIn](#) and [Twitter](#).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.